David E. Williams is President of the Health Business Group, a consulting firm that helps technology-enabled healthcare, medical device and pharmaceutical companies develop and execute innovative business strategies. He leads consulting teams, advises CEOs, is a member of corporate and non-profit boards, and chairs review panels for the federal government. He co-founded the company in 2003 after more than a decade as a consultant for the Boston Consulting Group and The LEK Partnership. David has a rare ability to explain complex healthcare concepts simply and clearly, making him a sought after expert for media such as NPR, Business Week, Fortune, US News and The Boston Globe. David produces the popular Health Business Blog and HealthBiz Podcast, where he has written more than 4000 posts since 2005 and conducted more than 100 podcast interviews with entrepreneurs, executives, scientists and political leaders. During the Massachusetts gubernatorial race, he interviewed all nine candidates about health policy.
Self-insured employers can’t fix healthcare—unfortunately, they’re stuck at the mercy of it. Nomi may save employers money and please providers, but there are drawbacks to paying directly. Because Nomi must ink contracts with each local provider and hospital, it will likely mean patients have a narrow network. This is good if you’re the preferred provider for an employer’s network—you’ll receive all those patients—but it means patients have fewer choices of providers for their care. That may work in a small community but would be less ideal in a large city. There’s also a chance that Nomi’s model may not encourage responsible behavior of employees, either, Williams says. Because employees aren’t paying a copay or a deductible, there’s a risk that they will overuse the medical system. They won’t think twice about going to a doctor.14 December 2021
It's obvious that the Russians are rushing the vaccine to market without adequate testing. It's possible that the vaccine will work, but there hasn't been enough time to verify that it's both safe and effective. The Russians haven't released any data that would support their claims. I don't think people will travel to Russia to receive the vaccine because, 1) they won't trust that it will work, 2) they could get COVID-19 on their travels to Russia, and 3) the Russians may allocate it to their own citizens. Vaccines have to be very safe to be worthwhile. As a hypothetical example, maybe 10 percent of people are expected to be infected with COVID-19, but 100% would be expected to get the vaccine. Even if the vaccine harms just one in 1,000 people, that is a lot of people and potentially more than COVID. It would be better to wait another few months for a vaccine that is proven to be safe and effective.7 October 2021
A deal with Beth Israel Lahey could help Joslin draw patients and is likely not big enough to worry regulators. There’s a question about if Joslin really could be viable on its own.7 October 2021